Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | 63.07% |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | -45.93% |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | -16.79% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | -79.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -79.54% |
| Mar 31, 2026 | 56.05% |
| Dec 31, 2025 | 15.10% |
| Sep 30, 2025 | 97.30% |
| Jun 30, 2025 | -9.81% |
| Mar 31, 2025 | -29.38% |
| Dec 31, 2024 | -15.23% |
| Sep 30, 2024 | -45.53% |
| Jun 30, 2024 | -42.45% |
| Mar 31, 2024 | 33.40% |
| Dec 31, 2023 | 52.89% |
| Sep 30, 2023 | 79.03% |
| Jun 30, 2023 | 87.36% |
| Mar 31, 2023 | 11.32% |
| Dec 31, 2022 | 87.34% |
| Sep 30, 2022 | 28.23% |
| Jun 30, 2022 | 41.02% |
| Mar 31, 2022 | 63.44% |
| Dec 31, 2021 | 120.04% |
| Sep 30, 2021 | 107.25% |